The distribution of 6/ 3 integrin in adhesion complexes at the basal membrane in human normal and cancer prostate glands was analyzed in 135 biopsies from 61 patients. The levels of the polarized 6/ 3 integrin expression at the basal membrane of prostate tumor glands were determined by quantitative immunohistochemistry. The 6/ 3 integrin expression was compared with Gleason sum score, pathological stage, and preoperative serum prostate -specific antigen ( PSA ). The associations were assessed by statistical methods. Eighty percent of the tumors expressed the 6 or 3 integrin and 20% was integrin -negative. Gleason sum score, but not serum PSA, was associated with the integrin expression. Low Gleason sum score correlated with increased integrin expression, high Gleason sum score with low and negative integrin expression. Three prostate tumor phenotypes were distinguished based on differential integrin expression. Type I coexpressed both 6 and 3 subunits, type II exclusively expressed 6 integrin, and type III expressed 3 integrin only. Fifteen cases were further examined for the codistribution of vinculin, paxillin, and CD 151 on frozen serial sections using confocal laser scanning microscopy. The 6/ 3 integrins, CD151, paxillin, and vinculin were present within normal glands. In prostate carcinoma, 6 integrin was colocalized with CD 151, but not with vinculin or paxillin. In tumor phenotype I, the 6 subunit did not colocalize with the 3 subunit indicating the existence of two different adhesion complexes. Human prostate tumors display on their cell surface the 6 1 and / or 3 1 integrins. Three tumor phenotypes associated with two different adhesion complexes were identified, suggesting a reorganization of cell adhesion structures in prostate cancer.
Introduction
Prostate carcinoma is the most commonly diagnosed visceral neoplasm in men and has become one of the nation's major health problems. However, its basic biology is still not well understood [ 1 ] .
A great biological variability in the rate of clinical progression is seen in prostate cancer patients. In addition, in most men afflicted with prostate cancer, there are multiple tumors showing variations in the morphologic pattern. DNA analysis and in situ hybridization studies showed that multiple tumors from the same prostate were genetically different and smaller tumors may give rise to distant lymph node metastasis [ 2, 3 ] . The hypothesis of the independent origin of multiple tumors in prostate cancer was also supported by the demonstration of discordant allelic deletion patterns on chromosomes 8p12 -21 and 17q21 in distinctly separate tumors [ 3 -5 ] .
A hallmark feature in all prostate cancers is the progressive loss of basal cells that are attached to the underlying extracellular matrix ( ECM ) in normal glands by two major junctional structures, the hemidesmosomes ( HDs ) and focal adhesions ( FAs ) [ 6, 7 ] . In neoplastic prostate cells, the formation of HDs and the expression of their components including laminin 5 [ 6, 7 ] , which is the extracellular ligand of the 64 integrin complex in HDs [ 8, 9 ] , are not observed. Thus, neoplastic cells do not express 4 integrin, a hemidesmosomal protein, at the basal membrane. Although integrins are downregulated in most human carcinoma, invasive prostate carcinoma shows a persistent expression of 3 and 6 integrins [ 10 ] .
In human skin, mutations in both alleles of either 6 or 4 integrins cause an inherited recessive blistering disorder called junctional epidermolysis bullosa associated with pyloric atresia ( PA -JEB ) [ 11, 12 ] . In cultured keratinocytes from a patient exhibiting a complete absence of the 4 integrin subunit, the 6 integrin subunit lacking its 4 partner formed a complex with the 1 subunit and redistributed with vinculin to FAs [ 12 ] , whereas in normal human keratinocytes, the 31 complex generally is recruited to FAs and the 64 integrins to HDs [ 13 ] . Both 6 and 4 null -mutant mice lacking HDs showed a widespread subepidermal blistering [ 14 -16 ] . Both 3 -null and 6 -null mutations were shown to be lethal [ 17 ] , whereas heterozygote 3 ± / 6 ± mice showed multiple defects in organ development including the urogenital tract revealing synergistic activities for these integrins during murine embryo development [ 16 ] . These observations indicate that the 64 and 31 integrins play an essential role in cell adhesion. In addition, the adhesion structures in skin contain the tetraspan TM4 protein designated CD151. CD 151 forms complexes with the 31 or 64 laminin -binding integrins and colocalizes with 64 in HDs in human skin [ 18 ] . HDs and FAs were shown to be dynamic and to change their molecular composition during their maturation [ 18 -21 ] .
Cell adhesion plays a crucial role in migration and invasion of malignant cells to distant tissues. It is suspected that the integrin expression is related to the invasive and migratory potential of tumors [ 22 -26 ] . Because prostate carcinoma shows a persistent expression of 6 and 3 integrins, we therefore examined the relationship of Gleason sum score, pathological stage, and preoperative serum prostate -specific antigen ( PSA ) with the 6 and 3 integrin expression. In this study, we observed three different prostate tumor phenotypes reflecting different adhesion structures in prostate cancer.
Materials and Methods

Clinical Material
For this study, 135 biopsy cores containing prostate carcinoma were analyzed from 61 men seen at the University of Arizona Health Sciences Center between 1993 and 1999. These biopsies were collected with IRB approval ( Assurance of Compliance no. M -1233 ). Men with a suspicious nodule on digital rectal examination or serum PSA levels greater than 4 ng / dl were biopsied transrectally under ultrasound guidance using a Biopty gun with an 18 -gauge spring loaded Trucut needle ( Biopty, Bard Urological Division, Covington, GA ). Sextant samples were typically obtained from the apex, midbase, and peripheral zones bilaterally. Immediately following biopsy, the tissue cores were oriented apex -tobase flat in the bottom of a metal embedding mold. The mold was carefully filled with OCT compound embedding media ( Miles, Diagnostic Division, Elkhart, IN ) and snap -frozen by immersion in a Freon cooled bath of isopentane using a Lipshaw Shandon Histobath ( Detroit, MI ). The tissues were stored at À 808C.
In this study, 56 men underwent subsequent radical retropubic prostatectomy ( RRP ). Five men elected not to have surgery. The removed prostates were totally embedded and used to accurately record Gleason sum scores [ 27 ] as well as pathologic stage. Serum PSA was presurgically obtained and at 6 -month intervals following RRP and was used to assess chemical recurrence. Two men died -one due to disseminated coccidiomycosis, and another one of his disseminated disease. Four men were lost to follow -up. Of the remaining 55 men, 7 men ( 8% ) developed evidence of residual disease with return of positive serum PSA greater than 0.02 ng / dl.
Immunohistochemistry
Samples of frozen biopsies were serially sectioned ( 3 -4 m ) with a cryostat. Serial sections were picked up on sequentially labeled, charged glass slides. For diagnosis and grading of the carcinoma lesions, sections of all 135 biopsies were stained with hematoxylin / eosin ( H&E ), and reacted with antibodies against cytokeratins 5 and 14 specific for basal cells, and with antibodies specific for 6, 3, and 4 integrins. For immunoperoxidase staining, frozen sections were fixed for 5 minutes in À 208C cold acetone, incubated in primary antibody diluted in PBS containing 1% BSA for 30 minutes at room temperature, and rinsed in three changes of PBS. Biotinylated secondary antibodies to mouse and rabbit were localized with biotinstreptavidin conjugated to horseradish peroxidase ( LSAB 2 kit; Dako, Carpinteria, CA ). The final color reaction was developed in diaminobenzidine substrate. Tissue sections were counterstained with hematoxylin.
Immunohistochemical Quantitation
H&E -stained sections of each biopsy core were examined for the presence of tumor and graded using the Gleason sum score system. Additional sequential sections were immunolabeled with antibodies specific for 3, 6, and 4 integrins and visualized by streptavidinbiotin DAB ( Dako ). Two observers using a double -headed scope viewed the H&E -stained sections together in order to agree on the areas of cancer. Then the scoring of the intensity of the integrin staining in each tumor was done separately by these two observers. Only integrin immunostaining polarized at the interface with the ECM of the carcinoma cells was considered positive. Diffuse cytoplasmic integrin staining was not scored. The 6, 3, and 4 integrin stainings were scored separately from each other. Thus, each biopsy obtained three scores. The immunostaining intensity was scored as follows: 1 = negative; 2 = weak; 3 = strong. The percentage of cancerous glands within each biopsy section showing clustering of the 6/3 integrin subunits at the basal membranes per tumor was scored as follows: 1 = 0% to 25%; 2 = 25% to 50%; 3 = 50% to 75%; and 4 = 75% to 100%. The final score of the staining in each biopsy was determined by multiplying the intensity score times the estimated percentage of the cancerous glands stained. Thus, a biopsy without polarized integrin staining at the interface to the ECM in cancerous glands would receive a final score of 1Â1 = 1. A biopsy showing strong polarized immunostaining at the interface to the ECM ( intensity score 3 ) in 75% to 100% of the cancerous glands ( percentage score 4 ) would obtain a final score of 3Â4 = 12. The ''withinpatient variability,'' which was not measured specifically, was taken into account by the percentage of glands showing this special integrin staining pattern. The combined score reflected both the intensity of staining and the extent of staining.
Confocal Laser Scanning Microscopy
For immunofluorescence microscopy, 15 selected frozen biopsies from 5 patients were serial sectioned with a cryostat, mounted on glass slides, fixed in À 208C acetone for 10 minutes, and then briefly air -dried. Primary antibodies were directly applied for 30 minutes, followed by three 5 -minute washes in PBS. Secondary antibodies were incubated for 30 minutes, and then rinsed off with three 5 -minute washes in PBS. Prior to mounting, the sections were rinsed in water, and then postfixed in 100% ethanol for 3 minutes.
Immunofluorescence was observed with a confocal laser scanning immunofluorescence microscope ( LSM 410; Carl Zeiss, Jena, Germany ). For simultaneous double -label fluorescence, an argon / krypton ion laser operating at 488 and 568 nm was used, together with a long -pass filter of 590 for visualization of Alexa 568 fluorescence and a band -pass filter of 515 to 540 for visualization of Alexa 488 fluorescence, respectively. RGB images were taken in highresolution mode using 1024Â1024 image points ( pixels ) and 8 -second scan time. Noise levels were reduced by line averaging of the scans.
Antibodies
Mouse monoclonal antibodies against cytokeratins 5 and 14 ( clones KA1 and KA2 ) were generated and characterized according to standard protocols [ 28 ] . Expression profile of 6 and 3 integrins polarized at the basal membranes of human prostate carcinoma epithelium. One hundred and thirty -five needle biopsy containing carcinoma obtained from 61 patients were analysed for the expression of the 6 and / or 3 integrin subunit and the intensity of the immunoreaction was scored: 2 to 12 = all expression; 2 to 8 = low expression; 9 to 12 = high expression. Graph ( A ) demonstrates the percentage of all biopsies analyzed ( 135 = 100% ) that expressed 6 and / or 3 integrin. The group of cases with the expression levels 2 to 12 included the cases with high expression levels 9 to 12, which also were analyzed separately ( A ). Graph ( B ) shows the expression profile of the integrin subunits in association with the tumor grading ( Gleason sum score ). The definitions of the descriptors are: 6, all cases which expressed 6 integrin; 3, all cases which expressed 3 integrin; integrin -negative, all cases which were integrin -negative. None of the tumors expressed polarized 4 integrin. The Gleason sum score was found to be inversely associated with the integrin expression.
was kindly provided by Dr. Eva Engvall ( The Burnham Institute, La Jolla, CA ) [ 29 ] . The rat monoclonal antibody specific for alpha 6 integrin clone J1B5 was generously provided by Dr. Caroline Damsky ( University of California, San Francisco, CA ) [ 30 ] .
Secondary antibodies used were Alexa Fluor 488 goat antimouse IgG and Alexa Fluor 568 goat antimouse or antirat IgG ( Molecular Probes, Eugene, OR ).
To reduce background and nonspecific reaction, the monoclonal antibody ( clone J1B5 ) specific for alpha 6 integrin was purified as follows: 100 ml of JIB5 conditioned medium was loaded onto a 5 -ml Hi -Trap protein G Sepharose column ( Amersham Pharmacia Biotech, Piscataway, NJ ). The column was washed with three column volumes of 100 mM Tris / HCl ( pH 7.9 ) and three column volumes of 10 mM Tris / HCl ( pH 7.9 ) followed by washing with two column volumes of 100 mM glycine ( pH 3.7 ). JIB5 was eluted with 15 column volumes of 100 mM glycine ( pH 2.8 ). The pH of the eluate was readjusted to pH 7.9 by adding 50 l of 1 M Tris / HCl ( pH 8.5 ) / ml eluate.
Statistical Method
An estimation of the intraclass correlation coefficient, which is defined as S T 2 /(S T 2 + S e 2 ), where S T 2 is estimation of between -patient variability and S e 2 is within -patient variability, was used to explore the intrapatient variability for measurement of Gleason sum score, 3, 6, or 3+ 6 integrins. Because the Gleason sum scores were correlated with each patient, the Generalized Estimating Equations ( GEE ) model was used to analyze the association between Gleason score and 3, 6, 3+ 6 integrins [ 31 ] . For the association between preoperative serum PSA and 3, 6, 3+ 6 integrins, the Spearman rank -order correlation was used [ 32 ] . The difference in expression between the phenotypes was evaluated by the Kruskal -Wallis test [ 33 ] .
Results
For this study, 135 biopsy cores containing prostate carcinoma from 61 men were analyzed for the polarized expression of 6, 3, and 4 integrins at the basal membrane of malignant prostate epithelium. The expression level concentrated at the basal membrane was scored ( 1 -12; 1 = negative, 2 = low, 12 = high ). In prostate carcinoma, both a diffuse surface pattern and a clustering of 6 and 3 integrins at the basal membrane were observed ( Figure 1 ; C and D ). The 6 and 4 integrins were also positive in blood vessels ( Figure 1 ; B and D ). Consistent with our previous results [ 10 ] , the polarization of 4 integrin at the basal membrane was not detected in any prostate tumor gland in which 6 and / or 3 integrins were clustered at the basal membrane ( Figure 1B ). Laminin 5, the extracellular ligand of the 64 integrin complex, was also found to be absent in these glands ( data not shown ).
The Expression Levels of 6/3 Integrins and Association with Gleason Sum Score and PSA Levels
The patients' preoperative PSA levels, Gleason sum score, and pathological stage of each tumor at the time of prostatectomy were recorded and compared to the integrin staining pattern.
Analysis of serial sections by immunohistochemistry revealed that 80% of the tumors examined expressed either 6 or 3 integrin ( Figure 2A ) . A total of 70% of the tumors expressed 6 integrin and 54% expressed 3 integrin within a range from low to high expression levels ( 2 -12 ) . Within the group of tumor glands showing high expression levels ( 9 -12 ) at the basal membrane ( Figure 2A ), 37% highly expressed either 6 or 3 integrin, 34% showed high levels of 6 integrin, 10% showed high levels of 3 integrin. Approximately 20% of the tumors examined showed no expression of either 6 or 3 integrin at the basal membrane.
Interestingly, three different phenotypes of prostate tumors were observed: 1 ) 44% of the tumors coexpressed both 6 and 3 subunits ( type I ), with 4.4% showing highlevel expression ( 9 -12 ) of both subunits ( Figure 2A ) ; 2 ) 26% of the tumors exclusively expressed the 6 subunit alone ( type II ), with 12.5% showing high expression levels (9-12) of 6 integrin only ( Figure 2A ) ; and 3 ) 10% of the tumors exclusively expressed the 3 subunit ( type III ) at the interface of the cell -ECM site ( Figure 2A ), with only a few tumors ( 0.74%; Figure 2A ) expressing high levels ( 9 -12 ) of the 3 subunit without expressing the 6 subunit. Because the expression values were not normally distributed, the Kruskal -Wallis test was performed to test the difference among the three tumor phenotypes. The differences for these three tumor phenotypes were statistically significant ( see Table 1 ).
Whether the group of integrin -negative tumors represent a fourth phenotype or is a result of poor preservation will require further examination. Because these specimens were snap -frozen immediately after biopsy, it is likely that these are truly integrin -negative.
The biopsies then were arranged into two groups according to the Gleason sum score ( 6, !7 ) and the integrin expression profile analyzed for these two groups ( Figure 2B ). Within the group of tumors with Gleason sum score 6, a total of 83% expressed 6 integrin, and 66% expressed 3 integrin ( Figure 2B ) . Neither of the two subunits was expressed in 5% of tumors in this group. From the tumors with Gleason sum score !7, a total of 29% of the tumors expressed 6 integrin, 27% expressed 3 integrin, and 54% showed no expression at all of either subunit at the basal membrane ( Figure 2B ). We questioned whether there was an association between Gleason sum score and PSA with 6, 3, or 6+ 3 integrin expression. The estimation of the intraclass correlation coefficient was computed for the Gleason sum score, 6, 3, and 6+ 3 ( Table 2A ). This test also included the group of integrin negative biopsies. The Gleason sum score was inversely associated with the 6 integrin expression ( P value .0272; Table 2B ). Low Gleason sum scores were significantly related to increased 6 expression levels at the basal membrane ( Figure 2B ) . Likewise, the Gleason sum score and 3 integrin expression ( P value .0001 ), and the Gleason sum score and both 6+3 integrin expression ( P value .0001 ) were inversely associated ( Table 2B ), Figure 2B ). There was also a significant correlation between Gleason sum score and the group of integrinnegative biopsies ( Figure 2B ). These integrin -negative biopsies were predominantly seen in the group of less welldifferentiated samples, with high Gleason sum scores suggesting that in these cases a nonintegrin adhesion receptor may be involved in cell -substrate attachment.
No association between serum PSA ( Table 3 ) and 6, 3, 6, and 3 integrin expression was observed.
The correlation between disease -free survival rate in patients with any of the three phenotypes could not be tested because no significant association between disease -free survival rate in patients and pathological stage or Gleason sum score was found in this study.
The Correlation of Phenotypes with Gleason Sum Score and Pathological Stage
The distribution of the three prostate tumor phenotypes in relation to the Gleason sum score was observed as follows: for Gleason sum score 6, 55% coexpressed both 6+ 3 integrin ( type I ), 29% of the tumors in this group expressed 6 integrin only ( type II ), whereas only 6.3% exclusively expressed 3 integrin ( type III; Figure 3A ). For Gleason sum score !7, 17% coexpressed both subunits ( type I ), 17% expressed 6 integrin only ( type II ), whereas 10% expressed 3 integrin only ( type III; Figure 3A ) . Taken together, these data suggest that increasing Gleason sum score selects against the predominance of a type I adhesion phenotype. Interestingly, 44% of the prostate tumors graded with Gleason sum score 7 and higher, which is correlated with decreased differentiation, was equally likely to express either phenotype I, II, or III ( Figure 3A ) .
A subset of tumors graded with Gleason sum score 6 ( 94 biopsies ) was analyzed for the expression pattern of the different phenotypes in relation to pathological staging. For stage T1a -T2c, 48% coexpressed 6 and 3 integrins, 28% expressed 6 integrin only, and 10% expressed 3 integrin only ( Figure 3B ). For stage T3a -T3b, 63% coexpressed 6 and 3 integrins, 21% expressed 6 only, and 15% expressed 3 integrin only ( Figure 3B ). For stage T3c, 52% coexpressed both 6 and 3 integrin, 41% expressed 6 integrin only, and none expressed 3 integrin only ( Figure 3B ).
In the subset of tumors ( 41 biopsies ) graded with Gleason sum score !7, the pathological stages were unevenly represented. For example, only two biopsies with stage T1a -T2c were available for the examination of the integrin expression; of these, one case expressed the 6 integrin only ( type II ), and the other was integrin -negative. For pathological stage T3c, eight biopsies were available. Of these, two tumors still expressed 6 integrin only ( type II ), one tumor expressed 3 only ( type III ), and the expression of 6+ 3 integrin ( type I ) was not observed. In stage T3a -T3b ( 26 biopsies; Figure 3D ), 22% expressed 6+ 3 integrin ( type I ), 19% expressed 6 integrin only ( type II ), and 11% expressed 3 integrin only ( type III ). Five biopsies were not staged because prostatectomy was not performed. Overall, these data indicate that in higher pathological stages, a selection for the expression of 6 integrin adhesion may occur and that the phenotype III ( 3 integrin only ) may be suppressed.
When analyzing the average expression intensities of the integrin subunits in each phenotype ( Figure 3C ) , it appeared that 6 integrin showed the highest intensity levels compared with the 3 integrin expression. Within the phenotype I, the average 6 and 3 expression levels were similar in the pathological stage T1a -T2c, whereas in stages T3 -T3b and T3c, the expression intensities for the 6 subunit were two -fold higher than for the 3 subunit ( Figure 3C ).
Immunofluorescence Localization of 6 and 3 Integrins in Normal and Neoplastic Prostate Glands
In normal prostate glands, the majority of the 6 integrin subunits pair with the 4 subunit, consistent with the formation of a hemidesmosomal structure. A minor amount of the 6 integrin subunit pairs with 1 integrin. The 61 integrin in cell cultures is associated with FAs containing, in part, vinculin and paxillin [ 34 ] . In prostate cancer however, the 4 integrin subunit and the majority of other integrin subunits ( with the exception of 1, 6, and 3 ) are no longer observed on the tumor cell surfaces [ 10 ] . The assembly of alpha -beta integrin complexes is required for the transport through the Golgi apparatus to the plasma membrane and for the exposure of integrin subunits on the cell surface [ 35 ] . In prostate tumor cells consequently, the 6 and the 3 subunits have to be expressed on the cell surface in a complex with the 1 subunit. To determine the 6 integrin location with respect to FAs in prostate cancer, we performed a double -staining immunofluorescence comparison of 6 integrin with vinculin and paxillin in frozen sections of normal and neoplastic prostate ( Figures 4 and 5 ) . In the normal prostate gland, 6 integrin, vinculin, and paxillin were intensely expressed at the basal membrane ( Figure 4 ) . The 6 integrin staining overlapped in some areas with both the vinculin and paxillin staining ( Figure  4; C and F ) . In other areas, the 6 integrin staining could be resolved from the vinculin or paxillin staining ( Figure  4 ; C and F ), reflecting that they did not colocalize. These data indicated heterogeneity of these adhesion complexes in the normal prostate gland. Vinculin, which is also known to contribute to E -cadherin containing cell -cell junctions in certain cell types, was expressed in the apical junctional region of the Luminal cells in normal glands ( not shown ). In addition to glands, vinculin and paxillin were also prominently expressed in the surrounding smooth muscle cells ( Figures 4A and 5 ; E and H ). The 6 -integrin was found to be strongly expressed in blood vessels ( Figures  1D and 7; A and E ).
In prostate cancer, the hemidesmosomal structures ( HDs ) and the clustered expression of hemidesmosomal proteins, especially the 4 integrin, are not observed. We questioned whether 6 integrin would colocalize with vinculin or paxillin to FAs in the absence of its HD partner 4 integrin in malignant prostate glands. For identification of cancerous and normal glands, sections were first analyzed by detecting simultaneously the 6 subunit and cytokeratins 5 and 14 ( Figure 4 ; A À C ). In normal cytokeratin 5 -and 14 -positive glands ( Figure 5 ; A À C ), the 6 integrin staining of the basal membrane appeared as a strong wide band ( Figure  5; A; D; G ), whereas in the cytokeratin 5 -and 14 -negative cancer glands, the 6 integrin staining appeared less intensely in a fine line ( Figure 5A ). Sections then were processed for simultaneous detection of 6 integrin and either paxillin ( Figure 5 ; D À F ) or vinculin ( Figure 5 ; G À L ). Both paxillin and vinculin were abundantly expressed in the smooth muscle cells, and less intensely at the glandular basal membranes. In addition, vinculin was also expressed in the apical junctional region of the luminal cells in the neoplastic glands ( Figure 5 ; H; I; K ; L ). In the absence of the 4 integrin subunit, we were surprised to discover that the 6 integrin did not colocalize with either paxillin ( Figure  5 ; D À F ) or vinculin ( Figure 5 ; J À L ) in the FAs of the malignant prostate glands. To determine whether 6 integrin colocalized with the tetraspan molecule CD151 in these malignant glands, we performed a double staining with antibodies specific for these two antigens. As shown in Figure 6 ; A À D ), 6 integrin colocalized with CD151 at the basal membranes of the malignant glands in most areas. CD 151 was also present in the basal membrane of normal prostate glands ( Figure 6A ). In addition, CD 151 was observed on the surface of epithelial cells in normal and neoplastic glands ( Figure 6A ).
To determine whether 6 and 3 integrins were involved in the same or in different adhesion complexes at the basal membranes in the type I cancer phenotype ( i.e., cancers expressing both subunits ), we performed a comparison of the two antigens in normal and in malignant prostate glands. In the normal prostate gland, the 6 and 3 integrins were strongly expressed in the basal membrane ( Figure 7A ), but were not found to be colocalizing when analyzed by high resolution ( not shown ). In prostate cancer glands expressing both subunits ( type I ), 6 and 3 integrins were not colocalized at the basal membranes ( Figure 7 ; C À E ). At high magnification, the 6 integrin staining could be resolved from the 3 integrin staining at the basal membrane ( Figure 7C ), suggesting the existence of two different cell -to -basal membrane adhesion sites and complexes in prostate cancer glands.
Discussion
In this study, we have identified three prostate tumor phenotypes expressing 6 and 3 integrins ( type I ), 6 integrin only ( type II ), or 3 integrin only ( type III ). Prostate carcinoma is a heterogeneous disease with a wide spectrum of pathologic and clinical manifestations. Most prostates with cancer were shown to contain spatially and distinctly separate tumors by the time of clinical diagnosis [ 36, 37 ] . Multiple tumors from the same prostate were shown by in situ hybridization and DNA analysis to be genetically different and that even smaller tumors may give rise to distant lymph node metastasis [ 2, 3 ] . The demonstration of discordant allelic deletion patterns on chromosomes 8p12 -21 and 17q21 in distinctly separate tumors supported the hypothesis of the independent origin of multiple tumors in prostate cancer [ 3 -5 ] . Our findings of the expression of different prostate tumor phenotypes were consistent with these previous observations showing the heterogeneity of prostate tumors.
In contrast to the findings in the 4 -negative PA -JEB skin keratinocytes [ 11 ] , we described in this study that the 6 integrin interestingly was not colocalized with vinculin or paxillin in primary prostate carcinoma. Because paxillin is a scaffold protein that provides docking sites for an array of signaling and structural proteins and also provides linkage to the actin cytoskeleton [ 38 ] , these data suggest the existence of different cell -ECM adhesion complexes in prostate tumors. Recently, cross linkers of the actin -filament systems with plasma membrane receptors other than paxillin have been described, such as the ERM ( ezrin, radixin, and moesin ) proteins [ 39 ] . These newer members of the ERM family were reported to play key roles in morphology, motility, signal transduction, and apoptosis [ 40, 41 ] . Furthermore, the finding in type I tumors -that the 6 integrin was not colocalized with the 3 integrin subunit -is consistent with a recent study, which demonstrated a heterogeneity in the composition of adhesion complexes [ 42 ] . It will be of great interest to isolate by laser capture microscopy techniques the proteins present within the 6 -containing adhesion sites in the tissue and determine their identity.
There is evidence that the morphology and molecular composition of FAs are dependent on laminin isoforms and on the integrins present in the complexes [ 43 ] . The activation of the 61 integrin alone or the 61 with 31 integrin leads to the formation of different adhesion complexes [ 43, 44 ] . The formation of adhesion complexes is crucial for signal transduction from the ECM into the cell and vice versa [ 45, 46 ] . Binding of integrins to extracellular ligands leads to a series of events including clustering of receptors, recruitment of FA linker proteins, actin polymerization, and a phosphorylation cascade [ 46 ] . A different ultrastructural arrangement of the molecules within the adhesion complexes could be linked to the transmission of different distinct signals. Consistent with this idea is our observation that CD 151, a molecule laterally associated with the 6 integrin, was present in prostate cancer, whereas vinculin and paxillin were absent. Recently, CD 151 has been implicated in novel signaling complexes inducing protein kinase C [ 47 ] .
The association of the integrin expression with the Gleason sum score was consistent with the fact that many human carcinomas have a decreased expression of integrins when compared with normal tissue [ 22 ] . However, for human pancreatic carcinoma, no correlation of integrin expression with tumor differentiation was observed [ 48 ] . Interestingly, 44% of the prostate tumors with a Gleason sum score !7 expressed either one of the described phenotypes. However, in differentiated tumors ( Gleason sum score 6) invading into the seminal vesicles ( pathological stage T3c ), only the phenotypes I ( 6 +3 integrin ) and II ( 6 integrin only ) with high expression levels of the 6 subunit were observed. This suggests that the clustered expression of 6 integrin may be correlated with invasion and the failure to express 3 integrin may be related to more aggressive tumors ( T3c ). There is evidence that the interaction of 31 with the adjacent basal membrane might transduce signals that inhibit the invasive behavior of epithelial cells [ 49, 50 ] , although its functional role is still poorly understood. In contrast, a role for the 61 integrin in invasion was suggested by previous studies [ 23, 51, 52 ] . Recently, the existence of a new subtype of 6 integrin lacking the extracellular ''beta -barrel'' domain was demonstrated in various cell types and was upregulated in cancer cells that exhibited migratory -enhancing properties [ 53 ] . This study also showed that the 6 -specific antibody ( GoH3 ) used here will not distinguish between the two 6 integrin forms [ 53 ] . Therefore, a switch between the 6 integrin subtypes from normal to cancer may have occurred. This is the subject of further study to determine the distribution of this novel structural variant within the three phenotypes.
The invasive potential of the tumor phenotypes expressing different adhesion complexes may also be determined by the availability or composition of their extracellular ligands. Laminins 5, 10, and 11 were shown to be preferred ligands for 31 [ 54 ] . The 61 integrin also was reported to be a major receptor for laminin 10 / 11 in human pancreatic carcinoma cells [ 55 ] and mouse hematopoietic cells [ 56 ] . A recent study showed that fibroblast adhesion to laminin 10 / 11 was mediated by both 31 and 61 integrins [ 57 ] . It will be of interest to determine the composition and localization of the different laminin forms within the three different integrin tumor phenotypes. Understanding the factors contributing to the invasive potential of prostate carcinoma is of fundamental importance in this disease.
Prostate cancer is unique in that latent and aggressive phenotypes exist. Currently used prognostic factors for the management of the disease include the histopathological evaluation of tumor size, grade, and localization and distribution within the gland [ 58 ] . For example, if invasion to the seminal vesicle had occurred, the disease -free 10 -year survival rate in patients decreased by approximately 50% as compared to the one in patients without seminal vesicle invasion [ 59 ] . Other studies showed that prostate cancers with established capsular penetration had a higher risk of progression than those with focal capsular penetration [ 60 ] . Capsular penetration is correlated with lymph node metastasis [ 61 ] . The preferred sites of metastasis in prostate cancer are lymph nodes and bone marrow -sites enriched with laminin 10 / 11 [ 62 ] . Taken together, these data suggest that retention of laminin 10 / 11 receptors by the cancer cells may play a role in prostate cancer metastasis.
The further understanding of integrin laminin receptors and the different integrin -containing adhesion phenotypes will contribute to determining their role in prostate cancer metastasis. We propose that the three tumor phenotypes, which are distinguished by differential integrin expression, will be useful for the separation of cases with organ -confined disease from cases with capsular penetration or with seminal vesicle invasion.
